Loading...
•
Jun 30, 2024
Ocuphire Q2 2024 Earnings Report
Ocuphire reported financial results for Q2 2024 and provided a corporate update.
Key Takeaways
Ocuphire Pharma reported a net loss of $7.8 million, or $(0.30) per share, for the second quarter ended June 30, 2024. The company's cash and cash equivalents totaled $41.4 million as of June 30, 2024, which is expected to fund operations into mid-2025. License and collaborations revenue was $1.1 million for the quarter.
VEGA-3 Phase 3 study of Phentolamine Ophthalmic Solution in Presbyopia is recruiting patients with top-line data expected in 2025.
LYNX-2 Phase 3 Study of Phentolamine Ophthalmic Solution continues enrollment with top-line data expected in 2025.
Preparatory steps towards Phase 2/3 with APX3330 in Diabetic Retinopathy are ongoing.
Cash position of $41.4 million provides runway anticipated into mid-2025.
Forward Guidance
Based on current projections, management believes that the cash on hand will be sufficient to fund operations for the next twelve months.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...